GlassScriptPhysician profile
Virendra P Sharma
NPI 1003807041
$3,385.56
in general payments reported to CMS, 2019-2025
31 companies · $618 in 2025
The $618 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $250 · 2021: $254 · 2022: $502 · 2023: $824 · 2024: $805 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $637.90 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $503.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $430.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $236.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $156.68 | 2019-2021 | |
| Abbott Laboratories | $151.69 | 2022-2025 | Freestyle Libre 2 |
| Novo Nordisk INC | $150.92 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $150.81 | 2020-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $115.21 | 2021-2025 | Mavyret |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.90 | 2021-2024 | Stiolto Respimat, Spiriva Respimat |
| Gilead Sciences, INC. | $81.32 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $75.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $73.32 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Dynavax Technologies Corporation | $62.38 | 2024 | Heplisav-B |
| Daiichi Sankyo INC. | $52.30 | 2024 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.63 | 2022 | |
| Csl Behring | $36.56 | 2023 | Kcentra |
| Smith+Nephew, INC. | $35.74 | 2023-2024 | Collagenase Santyl, Regranex |
| Lundbeck LLC | $33.20 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $32.29 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $29.40 | 2024 | Rexulti |
| Allergan, INC. | $25.98 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $24.94 | 2019 | |
| Verona Pharma, INC. | $23.39 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.64 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $22.25 | 2022 | |
| Dexcom, INC. | $19.28 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $17.44 | 2025 | |
| Axsome Therapeutics, INC. | $16.44 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $16.27 | 2024 | Trintellix |
| Philips North America LLC | $15.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virendra Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.